Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).
1 finding from 1 review
Hospital admissions · Adults with COVID‐19
Obesity Class II probably leads to higher hospitalisation(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
1 finding from 1 review
Hospitalisation (30 days, community) · Adults with COVID‐19
Obesity Class III may leads to higher hospitalisation (adjusted for DM, HTN, cardiovascular disease, age,… compared with normal BMI, Non‐obese, or BMI < 40 (low certainty).
2 findings from 1 review
Hospital admissions · Adults with COVID‐19
Obesity (Unclassified) probably leads to higher hospitalisation (adjusted for age, sex, DM, HTN, and cardiovascular… compared with normal Weight or Non‐Obese (moderate certainty).
1 finding from 1 review
Severe COVID · Adults with COVID‐19
Obesity (Unclassified) leads to higher severe COVID(30‐days, community) compared with normal Weight or Non‐Obese (high certainty).
1 finding from 1 review
Pneumonia · Adults with COVID‐19
Obesity (Unclassified) probably leads to higher pneumonia(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
1 finding from 1 review
Hospitalisation (30 days, community) · Adults with COVID‐19
Obesity (Unclassified) may leads to higher hospitalisation (30 days, community) compared with normal Weight or Non‐Obese (low certainty).
1 finding from 1 review
Hospitalisation (30 days, community) · Adults with COVID‐19
Every 5 units (kg/m2) increase in BMI may leads to higher hospitalisation(30 days, community) compared with N/A (low certainty).
1 finding from 1 review
Hospital admissions · Adults with COVID‐19
Obesity Class I probably leads to lower hospitalisation(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric recovery Defined as: WHZ ≥ −1.5 or MUAC > 125 mm for 2 consecutive visits and absence of nutritional oedema for 14 days (Alvarez Moran 2018b); absence of oedema and WHZ ≥ −1.5 or MUAC > 125 mm (Charle‐Cuellar 2021c; no oedema and we... · children aged > 6 months and < 5 years with wasting
It is very uncertain whether the intervention changes anthropometric recovery Defined as: WHZ ≥ −1.5 or MUAC > 125 mm for… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐response to treatment Defined as: not achieving weight‐for‐height > 85% of ideal or relapse requiring inpatient treatment (Linneman 2007)a; persistent oedema at 21 days or no weight gain in 2 consecutive visits (Ogobara Dougnon 2021)d; not mee... · children aged > 6 months and < 5 years with wasting
It is very uncertain whether the intervention changes non‐response to treatment Defined as: not achieving… (very low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: MUAC gain per day Defined as (discharge MUAC − admission MUAC)/days in treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: mean weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/admission weight)/days in treatment (Wilunda 2021)e · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: median weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/weight on admission)/days on treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Transfer to inpatient care Defined as referral for: presence of danger signs and failed appetite test on first day of treatment (Alvarez Moran 2018)b; appearance of severe signs of illness, persistent oedema, absence of weight gain in non‐oedemato... · children aged > 6 months and < 5 years with wasting
It is very uncertain whether the intervention changes transfer to inpatient care Defined as referral for: presence of… (very low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: weight gain per day (g/kg/day) Calculated as ((discharge weight − admission weight)/weight on admission)/days in treatment among recovered children (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review